How to identify and evaluate new tumour markers 

Major advances have been achieved in targeted immunotherapy with significant clinical benefits for patients. However, on-target/off-tumour toxicity is still a major concern, which highlights the clinical need for better targets to improve the safety profile of immunotherapies.  

On-target/off-tumour toxicity is mainly based on the expression of tumour-associated antigens (TAA) in healthy tissues under physiological conditions. New approaches have to be developed to increase the level of specificity of targeted immunotherapy towards cancerous cells.  

In this free webinar, Dr. Christoph Herbel, Team Coordinator in the Research and Development department at Miltenyi Biotec, presents a new workflow to identify and evaluate new tumour markers using an unbiased high-throughput, flow cytometry–based screening and multiparameter imaging that helps to overcome these challenges.  

Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec. 

It took place on 14 Dec, 4PM GMT, 5PM CET. 

Watch on Demand for free here.


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free